ReviewCancers2022
Claudins and Gastric Cancer: An Overview.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 4 syntheses or guidelines pooled it, 136 citations in OpenAlex.
- The prognostic value of CLDN18.2 expression in pancreatic ductal adenocarcinoma: a systematic review and individual patient data meta-analysis.Virchows Archiv : an international journal of pathology · 2026Pooled it
- Zolbetuximab in the treatment of advanced gastric and gastroesophageal junction cancer: a systematic review.Frontiers in immunology · 2026Pooled it
- Efficacy of ChemoimmunotherapyCurrent medicinal chemistry · 2024Pooled it
- RHOA protein expression correlates with clinical features in gastric cancer: a systematic review and meta-analysis.BMC cancer · 2022Pooled it
- Knocking down CLDN7 enhanced the effect of cisplatin in OC cells by regulating mitophagy.Journal of ovarian research · 2026Article
- Pretreatment Claudin-18.2 Expression Predicts Poorer Survival Outcomes in Locally Advanced Gastric Cancer Treated with Perioperative Chemotherapy.Diagnostics (Basel, Switzerland) · 2026Article
- Tissue Claudin 18.2 levels as a prognostic factor in gastric adenocarcinomas: A retrospective cohort study.Medicine · 2026Article
- The PRKN/METTL3/CLDN2 axis promotes colorectal cancer development through epigenetic mechanisms.Cell biology and toxicology · 2026Article
- Comparison of the Efficacy of 35 Anticancer Drugs According to Genomic Profiling and Biological Characteristics of 14 Gastric Cancer Cell Lines.International journal of molecular sciences · 2026Article
- Claudins proteins in brain tumors: expression patterns and therapeutic target.Biochemia medica · 2026Review
- Article
- Tight junction proteins: Gatekeepers turned facilitators in the pathogenesis of gastric adenocarcinoma.World journal of gastrointestinal oncology · 2026Review
- Multi-omics analysis identifies CLDN10 as a B-cell-associated prognostic biomarker in HPV-negative head and neck squamous cell carcinoma.Frontiers in cell and developmental biology · 2026Article
- The Age of Molecular Biomarkers: Cancer in the Era of Personalized Medicine. What Do Pathologists in Developing Countries Need to Know and Understand?International journal of general medicine · 2026Review
- Concordance of claudin-18.2 expression in biopsy, resection, and recurrent specimens: implications for zolbetuximab therapy in pancreatic ductal adenocarcinoma.Tissue barriers · 2026Article
- Involvement of claudins 6 and 9 in epithelial-mesenchymal transition and the metastatic process.Tissue barriers · 2026Review
- Early-life rotavirus infection susceptibility and later gastrointestinal cancer protection: Reverse antagonistic pleiotropy and potential vaccine benefits.Current research in microbial sciences · 2026Article
- Article
- RBMX2 linkseLife · 2025Article
- NK Cell-Derived Small Extracellular Vesicles Armed With CLDN4-Targeting Peptides Potentiate Radiotherapy in Gastric Cancer.Journal of extracellular vesicles · 2025Article
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite recent improvements in diagnostic ability and treatment strategies, advanced gastric cancer (GC) has a high frequency of recurrence and metastasis, with poor prognosis. To improve the treatment results of GC, the search for new treatment targets from proteins related to epithelial-mesenchymal transition (EMT) and cell-cell adhesion is currently being conducted. EMT plays an important role in cancer metastasis and is initiated by the loss of cell-cell adhesion, such as tight junctions (TJs), adherens junctions, desmosomes, and gap junctions. Among these, claudins (CLDNs) are highly expressed in some cancers, including GC. Abnormal expression of CLDN1, CLDN2, CLDN3, CLDN4, CLDN6, CLDN7, CLDN10, CLDN11, CLDN14, CLDN17, CLDN18, and CLDN23 have been reported. Among these, CLDN18 is of particular interest. In The Cancer Genome Atlas, GC was classified into four new molecular subtypes, and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.